A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

Inclusion Criteria: * Simultaneous kidney/pancreas transplant recipients * Insulin dependent Type 1 or 2 diabetes pretransplant * Recipient age 18-65 years * Donor age 5-65 years * Women must have negative serum pregnancy test and practice birth control for study duration * Negative T-cell crossmatch * Parent (or guardian) is able to understand the consent form and give written informed consent Exclusion Criteria: * Prior treatment with daclizumab * Known sensitivity or contraindication to tacrolimus, MMF, or steroids * Patient with significant or active infection * Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and recipient serum * Patients whose life expectancy is severely limited by diseases other than renal disease * Ongoing substance abuse, drug or alcohol * Major ongoing psychiatric illness or recent history of noncompliance * Insufficient cardiovascular reserve * Malignancy within last 5 years, excluding nonmelanoma skin cancers * Serologic evidence of infection with HIV or Hepatitis B surface antigen positive * Investigational drug within 30 days prior to transplant surgery * Anti-T cell therapy within 30 days prior to transplant surgery